You are here

SANARIA INC.

Company Information
Address
9800 MEDICAL CENTER DR STE A209
ROCKVILLE, MD 20850-6395
United States


http://www.sanaria.com

Information

UEI: YLF2SS2NYGC5

# of Employees: 67


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR-Success: Envisioning a World Without Malaria

    Travelers, military personnel, and residents in malaria-stricken countries face a choice: follow a sometimes daily medication regimen that can be costly for the very poor or risk contracting a disease that sickened 219 million and killed almost half of a million people in 2017.While nations have...
  2. SBIR-STTR-Success: Sanaria Inc.

    It may seem hard to top working on the Human Genome Project, but for Dr. Stephen L. Hoffman, Sanaria founder, that was just one step towards helping to eradicate malaria. Annually, malaria caused by Plasmodium falciparum causes greater than 200 million clinical cases and approximately 0.5 million...

Award Charts




Award Listing

  1. A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage

    Amount: $999,880.00

    ABSTRACT In 2020 malaria caused 241M clinical cases and 627,000 deaths, the greatest numbers of annual deaths since 2012. There were more deaths in Africa from malaria than from COVID-19. There is an ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Progressing PfSPZ vaccines for malaria to licensure and commercialization

    Amount: $999,921.00

    ABSTRACT Sanaria’s mission is the licensure and marketing of Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines against malaria that will prevent malaria infection and transmission in individuals ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  3. Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines

    Amount: $300,000.00

    Project Abstract In 2020 malaria cases (241M) and deaths (627,000) reached the highest since 2012 emphasizing the urgent need for new tools for prevention, control, and elimination of this disease. Sa ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  4. Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro

    Amount: $282,240.00

    In 2022 WHO called for highly efficacious vaccines against malaria that prevent Plasmodium falciparum (Pf) infection in rt 90% of recipients. Alone among malaria vaccines, Sanaria® PfSPZ (Pf sporozoi ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  5. Development of monoclonal antibody-mediated interventions to combat malaria

    Amount: $298,596.00

    This contract is to provide proof of concept studies for the development of a monoclonal antibody to combat P. falciparum malaria.

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  6. PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria

    Amount: $988,772.00

    ABSTRACT The aim of this project is to conduct a pivotal clinical trial of Sanaria’s Plasmodium falciparum (Pf) whole sporozoite (SPZ) vaccine, Sanaria® PfSPZ Vaccine, to support licensure for trav ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  7. A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

    Amount: $1,967,457.00

    We propose to further enhance Plasmodium falciparum (Pf) Sporozoite (SPZ)-based vaccines against malaria that are the only immunogens proven to induce rt90% short term (3 weeks) and long term (at leas ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  8. In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine

    Amount: $600,000.00

    ABSTRACT In 2020 malaria caused 241M clinical episodes and 627,000 deaths, a significant increase from 2019. There were more deaths in Africa from malaria than from COVID-19. There is an urgent unmet ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  9. A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products

    Amount: $3,000,000.00

    PROJECT ABSTRACT: According to the World Health Organization, the 228 million cases of malaria in 2018 were an increase of ~16 million cases over 2015 while the number of deaths was 405,000, not subst ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  10. Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray

    Amount: $600,000.00

    PROJECT SUMMARY: PfSPZ Vaccine, supported in clinical development by the International PfSPZ Consortium, is on track to be the first US FDA-licensed vaccine against malaria or any human parasitic dise ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government